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EXENDIN-4 REDUCES ATHEROSCLEROSIS AND NASH iNTroDUcTioN
Cardiovascular disease (CVD) due to atherosclerosis is the leading cause of morbidity and mortality in the Western world. There is a strong association between atherosclerosis and non-alcoholic fatty liver disease (NAFLD), which raised the interest of the role of the liver in the development of atherosclerosis. NAFLD embraces a pathological spectrum of liver diseases, from steatosis with virtually no evidence of hepatocellular injury or liver inflammation to non-alcoholic steatohepatitis (NASH) and cirrhosis 1 . NASH is characterized by accumulation of fat in the liver in combination with hepatic inflammation 2 . This inflammatory response was assumed to be the consequence rather than the cause of the disease. However, compelling data point to a central initiating role of monocyte recruitment and macrophage activation in the progression of hepatic inflammation in a similar way as in the development of atherosclerosis as we recently reviewed 3 . The potential of a shared etiology between inflammation in the liver and vessel wall leads to putative intervention therapies to tackle both disorders at the same time by targeting macrophage infiltration. This is particularly interesting, since the current standard therapies to reduce inflammation in NASH have only limited effectiveness. Lifestyle intervention, including exercise, is recommended in patients with NASH. However, it appears to be difficult to achieve improvements in NASH in the long run and pharmacological intervention is ultimately required 4 .
Glucagon-like peptide-1 receptor (GLP-1R) agonists, such as exendin-4, are currently being validated for the treatment of type 2 diabetes mellitus and have been shown to increase glucose-dependent insulin secretion, to regulate gastric emptying, and to reduce food intake and body weight 5 . In addition to improving glycemic control, GLP-1R activation improves lipid metabolism. We 6 and others [7] [8] [9] have shown that GLP-1R activation reduces hepatic steatosis, increases hepatic lipid oxidation, decreases lipogenesis, and attenuates hepatic VLDL production.Collectively, these data indicate the potential of GLP-1R activation to treat NAFLD, but the impact on liver inflammation and atherosclerosis is still uncertain. Moreover, contrasting results have been reported regarding the effects on atherosclerosis in ApoE -/mice. While Gaspari et al. 10 showed clear inhibiting effects on the progression of atherosclerosis, Panjwahi et al. 11 did not observe any effects on atherosclerosis development. It should be noted that these mice do not respond to lipid-lowering therapy and lack apoE, a crucial factor for cholesterol efflux from macrophages. Given this controversy, combined with the reduction in hepatic steatosis, it is of significant importance to further explore the therapeutic potential of GLP-1R activation to impact on inflammation in both the liver and vessel wall. 9 165 
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Plasma CETP concentration
Plasma CETP concentration was measured using the DAIICHI CETP ELISA kit according to manufacturer's instructions (Daiichi, Tokyo, Japan).
Atherosclerosis quantification and monocyte adhesion to the endothelium wall After 4 weeks of treatment, mice were sacrificed and perfused with ice-cold PBS via the heart. Hearts were isolated and fixed in phosphate-buffered 4% formaldehyde, dehydrated, embedded in paraffin and cross-sectioned (5 µm) through the aortic root area. Cross-sections were stained with hematoxylin-phloxine-saffron to determine lesion area and lesion severity as described before 13, 14 . Briefly, various types of lesions were discerned: no lesions, mild lesions with fatty streak-like lesions containing foam cells, and severe lesions referred to advanced lesions containing foam cells in the media, presence of fibrosis, cholesterol clefts, mineralization and/or necrosis. Additionally, cross-sections were stained with AIA 31420 antiserum (1:3000, Accurate Chemical and Scientific, Westbury, NY, USA) to determine macrophage area and monocyte adhesion to the endothelium wall as described 15 . Lesion area and macrophage area were determined using Leica Qwin-software.
Hepatic lipid content
After 4 weeks of treatment, mice were sacrificed and perfused with ice-cold PBS via the heart, and livers were isolated. Lipids were extracted according to a modified protocol from Bligh and Dyer 16 . Briefly, small liver pieces were homogenized in ice-cold methanol. After centrifugation, lipids were extracted by addition of 1800 µl CH 3 OH: CHCl 3 (1:3 v/v) to 45 µL homogenate, followed by vigorous vortexing and phase separation by centrifugation (5 min at 2,000 rpm). The CHCl 3 phase was dried and dissolved in 2% Triton X-100. TG and TC concentrations were measured as described above. Phospholipids (PL) concentration was measured using a commercial kit (phospholipids B, Wako Chemicals, Neuss, Germany). Liver lipids were expressed as nmol per mg protein, which was determined using the BCA protein assay kit (Pierce, Rockford, IL, USA).
Hepatic gene expression analysis
Total RNA was extracted from liver pieces using the Nucleospin RNAII kit (Macherey-Nagel, Duren, Germany) according to manufacturer's instructions. RNA quality was examined by the lab-on-a-chip method using Experion Std Sens analysis kit (Biorad, Hercules, CA) and RNA concentration was determined by Nanodrop technology (Thermo 166 Scientific, Wilmington, USA). Total RNA was reverse-transcribed with iScript cDNA synthesis kit (1708891, Bio-Rad), and the obtained cDNA was purified with Nucleospin Extract II kit (636973, Macherey-Nagel, Bioké). Real-time PCR was performed on a CFX96 machine (Bio-Rad), the reaction mixture consisting of SYBR-Green Sensimix (QT615, GC Biotech), cDNA, primers (Biolegio, Nijmegen, The Netherlands; see Supplemental Table 1 for primer sequences), and nuclease-free water in a total reaction volume of 10 µL. mRNA values of each gene were normalized to mRNA levels of cyclophilin (Cyclo) and hypoxanthine ribosyltransferase (Hprt). Data were calculated as fold difference as compared with the PBS control group. 
Statistical analysis
All data are presented as means ± SEM. Statistical differences between groups were assessed with the Mann-Whitney U test for two independent groups. A P-value of less than 0.05 was considered statistically significant. decreased VLDL-cholesterol and slightly increased HDL-cholesterol levels (Fig. 1C) . The latter effect was accompanied by a 26% increased hepatic expression of apolipoprotein A1 (Apoa1), encoding the major lipoprotein of HDL (Fig. 1D ). 
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Exendin-4 largely suppresses atherosclerosis development and monocyte recruitment in the aortic root Despite slightly attenuating dyslipidemia, exendin-4 treatment markedly reduced total atherosclerotic lesion area as compared to controls (-33%; P<0.05) ( Fig. 2A) . Additionally, mice treated with exendin-4 showed more lesion-free sections (+63%; P=0.07) and less severe lesions (-42%; P<0.05) as compared to PBS controls (Fig. 2B) . Moreover, exendin-4 significantly reduced the number of monocytes adhering to the endothelium wall in the aortic root (-42%, P<0.001, Fig. 2C ) as well as the macrophage area in the plaque (-44%, P<0.05, Fig. 2D ). Fig. 3C ). In line with these data, exendin-4 decreased hepatic CD68 + macrophages (-18%, P<0.05; Fig. 3D ) and F4/80 + macrophages (-25%, P<0.001; Fig. 3E ). 
Exendin-4 reduces macrophage infiltration into the liver
To elucidate the mechanism underlying the reduction of liver macrophage content by exendin-4, we first determined the hepatic gene expression of monocyte chemotactic
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protein-1 (Mcp-1), which mediates monocyte recruitment from the circulation to sites of infection and inflammation. As shown in Fig. 4A , exendin-4 reduced Mcp-1 expression (-34%; P<0.05). This was accompanied by a reduction of macrophages positive for Mac-1, an infiltrating macrophage marker (-36%, P<0.01; Fig. 4B ). Exendin-4 does not affect circulating antibodies against oxLDL, but reduces oxLDL uptake by macrophages
Since the uptake of oxLDL by macrophages can drive both atherosclerosis and NASH, we first measured specific antibodies against oxLDL in the circulation. Exendin-4 did not affect oxLDL-specific IgG1, IgG2a, and IgM levels in plasma (Fig. 5A) . Next, to determine if exendin-4 can impact on oxLDL uptake by macrophages, we incubated peritoneal macrophages with [ 3 H]COEth-oxLDL (10 µg/ml) for 48 h with or without exendin-4 (0.05 and 0.5 nM). Exendin-4 decreased the uptake of [ 3 H]COEth-oxLDL (up to -33%, P<0.01) compared to controls (Fig. 5B ). This effect was completely abolished by pre-treatment of the cells with exendin-9 (Fig. 5B) , which demonstrates that exendin-4 reduces oxLDL uptake by activating the GLP-1R. Oil-red O staining confirmed that exendin-4 reduced foam cell formation, which was blocked by exendin-9 (Fig. 5C ).
DiscUssioN
In this study, we investigated the effect of exendin-4 treatment on liver inflammation in addition to the development of atherosclerosis in E3L.CETP mice fed a Westerntype diet. Our data show that 4 weeks of exendin-4 infusion markedly decreases total atherosclerotic lesion area, accompanied by a reduction in plaque macrophages. In parallel, exendin-4 caused a marked reduction in hepatic lipids and macrophages as well as hepatic inflammation, hallmarks of NASH.
It is interesting to note that short-term treatment with exendin-4, as compared with vehicle, caused a substantial reduction in atherosclerosis albeit that exendin-4 only slightly affected cholesterol levels and the lipoprotein profile. Therefore, the anti-atherogenic effect of exendin-4 is likely largely independent of modulation of plasma lipid levels. This observation contrasts the effects of classic lipid-lowering compounds including atorvastatin, which reduce atherosclerosis in E3L.CETP mice mainly by reducing apoB-containing lipoproteins 14 . We found that exendin-4 inhibited the adherence of monocytes to the vessel wall and decreased the macrophage area of the plaque, suggesting that exendin-4 decreases the recruitment of monocytes into the vessel wall. Our finding add to previous findings demonstrating that 4 weeks of GLP-1 receptor activation decreases atherosclerotic development without reducing plasma lipids in ApoE -/mice 10, 18, 19 . Although a recent study did not find a reduction in atherosclerosis in ApoE -/mice 11 , this might be related to potential tissue heterogeneity in GLP-1 receptor expression in the ApoE -/mice as well as variations in the experimental set-up (e.g. animal age, treatment regimen).
Second, we observed that exendin-4 reduced the lipid content of the liver, which EXENDIN-4 REDUCES ATHEROSCLEROSIS AND NASH was accompanied by a reduction in inflammatory markers and macrophage content of the liver as judged from hepatic gene and protein expression. It is known that feeding hyperlipidemic mice a diet containing cholesterol increases the hepatic macrophage content already within a few days 20 . Since in our study mice were fed the Western-type diet for 5 weeks before starting treatment, exendin-4 may thus have reduced the hepatic macrophage content either by reducing the infiltration of activated macrophages from the circulation or by inducing the elimination of macrophages from the liver. The current study design does not allow us to discriminate between these possibilities.
However, we did observe a decrease in hepatic MCP-1 expression along with a reduction in Mac-1 + infiltrating macrophages, suggesting that reduced recruitment of monocytes/macrophages from the circulation to the liver contributes to the reduction in total macrophages. Collectively, we show that exendin-4 treatment affects important features of NASH, including reduction of liver macrophages as well as lipid content.
Historically, NASH was thought to be a causal risk factor for cardiovascular disease (CVD) as patients with NASH have a higher mortality risk than the general population, mainly due to CVD 2 These are all processes which likely lead to inhibition of monocyte/macrophage adhesion to the vessel wall and the liver. The importance of blood monocytes in the development of atherosclerosis has been firmly established 21 , and accumulating evidence demonstrates the role of hepatic infiltration of blood-borne monocytes in liver inflammation 22, 23 . In fact, the migration of immune cells into the liver appears to be one of the first critical steps in both acute and chronic liver inflammation, mediating innate and adaptive inflammatory responses, which result in ongoing immune cell recruitment, tissue damage, and fibrosis 23 .
As a second mechanism explaining the reduction of macrophage recruitment, we showed that exendin-4, via the GLP-1R, reduces the uptake of oxLDL by peritoneal macrophages and, as a consequence, reduced foam cell formation in vitro. These data are in full accordance with previous observations showing that native GLP-1 also 9 176 reduces oxLDL uptake by peritoneal macrophages thereby reducing atherosclerosis development from ApoE -/mice 19 . We did not observe any changes in plasma anti-oxLDL antibodies after exendin-4 treatment, indicating that exendin-4 probably does not affect the oxLDL levels in plasma. Since native GLP-1 decreased the macrophage protein levels of CD36 19 , involved in the uptake of modified LDL, it is likely that in our study exendin-4 exerts its protective effects on macrophage foam cell formation by a similar mechanism. The relevance for oxLDL uptake via scavenger receptors by macrophages in atherosclerosis development has been confirmed by many studies 24 . Recent studies have shown that oxLDL uptake via scavenger receptors is also an important risk factor for the progression to hepatic inflammation 15 . In fact, inhibition of oxLDL uptake and thus foam cell formation by deficiency of the scavenger receptors CD36
and scavenger receptor class A in hematopoietic cells reduces hepatic macrophage infiltration 25 , confirming that oxLDL uptake by macrophages not only plays a vital role in atherosclerosis development but also regulates hepatic inflammation. 
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Collectively, we hypothesize that the protective effect of exendin-4 against inflammation in both the vessel wall and liver can be explained by (1) reducing monocyte/macrophage recruitment from the circulation and by (2) inhibiting the uptake of oxLDL by macrophages and the subsequent activation and formation of foam cells at these locations (see Fig. 6 ). Interestingly, we also observed that exendin-4 decreased hepatic CETP gene expression (-34%, P<0.05) and plasma CETP concentration (-15%, P<0.01) (Supplemental Fig. S2 ). Recently, we demonstrated similar effects for niacin, which were explained by a reduction in macrophages that largely contribute to hepatic CETP expression 26 .
In our present study, hepatic CETP expression positively correlated with the hepatic expression of the macrophage markers CD68 (R 2 =0.332; P<0.001) and F4/80 (R 2 =0.607;
P<0.001) (Supplemental Fig. S3 ), indicating that exendin-4 also reduces CETP expression by reducing the hepatic macrophage content. Since CETP is involved in the transfer of cholesteryl esters from HDL to (V)LDL, the reduction in CETP may have contributed to the slight decrease in (V)LDL/HDL ratio, and thereby to reduced atherosclerosis development. Taken together, these data suggest that reducing NASH in general, by reducing the macrophage content, may reduce CETP expression, thereby improving the lipoprotein profile and therefore decrease the risk of developing atherosclerosis.
Thus far, there is no established pharmacological compound to treat NASH. Lifestyle modifications, such as weight loss, exercise, and restriction of nutrition intake are still the mainstays for the treatment of NASH 27 . Although lipid-lowering agents (e.g. statins and fibrates) and anti-oxidants (e.g. vitamins C, E) have beneficial effects on atherosclerosis development, none of them have shown adequate and convincing benefits in the treatment of NASH 28, 29 . Exendin-4 has been approved for the treatment of T2DM 5 and has also been shown to possess cardioprotective actions that include, in addition to reducing atherogenesis, suppression of arrhythmias, heart failure, myocardial infarction, and death 30 . Based on our collective findings that exendin-4 reduces high fat diet-induced hepatic steatosis by decreasing lipogenesis 6 and suppresses macrophage content in both vessel wall and liver (in the current study), we propose that exendin-4 is a suitable candidate to concomitantly treat atherosclerosis and NASH.
In conclusion, our findings show that exendin-4 treatment reduces inflammation in both the liver and vessel wall in E3L.CETP mice fed a Western-type diet, by reducing monocyte/macrophage recruitment and inhibiting the uptake of oxLDL by macrophages. We anticipate that exendin-4 can be used as a valuable strategy to treat NASH and atherosclerosis in addition to T2DM, especially in patients who display a combination of these diseases. 
